|
|
| | WNTinib (Synonyms: APS-8-100-2) Basic information |
| Product Name: | WNTinib (Synonyms: APS-8-100-2) | | Synonyms: | WNTinib (Synonyms: APS-8-100-2);WNTinib;2-Pyridinecarboxamide, 4-[3-fluoro-4-[[[[4-(1,1,2,2,2-pentafluoroethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- | | CAS: | 2770091-44-4 | | MF: | C22H16F6N4O3 | | MW: | 498.38 | | EINECS: | | | Product Categories: | | | Mol File: | 2770091-44-4.mol |  |
| | WNTinib (Synonyms: APS-8-100-2) Chemical Properties |
| Boiling point | 490.895±45.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.469±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 12.130±0.70(predicted) | | form | Solid | | color | White to off-white |
| | WNTinib (Synonyms: APS-8-100-2) Usage And Synthesis |
| Uses | WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β-catenin (CTNNB1) mutated hepatocellular carcinoma (HCC). WNTinib downregulates oncogenicWntsignaling by inhibiting KIT/MAPK and downstream EZH2 activation[1]. | | in vivo | WNTinib (20 mg/kg; p.o.; 0-24 h) has a half-life of 9.38 hour, plasma concentration of 7 μM 24h after oral dosing and detectable quantities of drug in blood plasma up to 72h post-dosing[1]. | Animal Model: | mice[1] | | Dosage: | 20mg/kg | | Administration: | Tail vein injection; 5 days | | Result: | inhibited tumors |
| | References | [1] Rialdi A, et al. WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Nat Cancer. 2023 Aug;4(8):1157-1175. DOI:10.1038/s43018-023-00609-9 |
| | WNTinib (Synonyms: APS-8-100-2) Preparation Products And Raw materials |
|